BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mankoff DA, Link JM, Linden HM, Sundararajan L, Krohn KA. Tumor receptor imaging. J Nucl Med 2008;49 Suppl 2:149S-63S. [PMID: 18523071 DOI: 10.2967/jnumed.107.045963] [Cited by in Crossref: 117] [Cited by in F6Publishing: 120] [Article Influence: 7.8] [Reference Citation Analysis]
Number Citing Articles
1 van Lith SAM, Raavé R. Targets in nuclear medicine imaging: Past, present and future. Nuclear Medicine and Molecular Imaging 2022. [DOI: 10.1016/b978-0-12-822960-6.00069-7] [Reference Citation Analysis]
2 Sheikh A, Md S, Kesharwani P. Aptamer grafted nanoparticle as targeted therapeutic tool for the treatment of breast cancer. Biomed Pharmacother 2021;146:112530. [PMID: 34915416 DOI: 10.1016/j.biopha.2021.112530] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
3 Sheikh A, Md S, Kesharwani P. RGD engineered dendrimer nanotherapeutic as an emerging targeted approach in cancer therapy. J Control Release 2021;340:221-42. [PMID: 34757195 DOI: 10.1016/j.jconrel.2021.10.028] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 10.5] [Reference Citation Analysis]
4 Shaghaghi Z, Alvandi M, Ghanbarimasir Z, Farzipour S, Emami S. Current development of sigma-2 receptor radioligands as potential tumor imaging agents. Bioorg Chem 2021;115:105163. [PMID: 34289426 DOI: 10.1016/j.bioorg.2021.105163] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
5 Shukla J, Vatsa R, Walia R, Chhabra A, Rana N, Singh H, Kumar R, Mittal BR. Development of Ga-68 DOTA-CRH for PET/CT Imaging of ACTH-Dependent Cushing's Disease: Initial Study. Cancer Biother Radiopharm 2021. [PMID: 34191604 DOI: 10.1089/cbr.2020.4686] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 DE Vries HM, Schottelius M, Brouwer OR, Buckle T. The role of fluorescent and hybrid tracers in radioguided surgery in urogenital malignancies. Q J Nucl Med Mol Imaging 2021;65:261-70. [PMID: 34057342 DOI: 10.23736/S1824-4785.21.03355-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
7 Wu J, Yuan Y, Tao XF. Targeted molecular imaging of head and neck squamous cell carcinoma: a window into precision medicine. Chin Med J (Engl) 2020;133:1325-36. [PMID: 32404691 DOI: 10.1097/CM9.0000000000000751] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
8 Mankoff DA. PET Imaging in Cancer Clinical Trials. Molecular Imaging 2021. [DOI: 10.1016/b978-0-12-816386-3.00082-x] [Reference Citation Analysis]
9 Nomura S, Taichi M, Tanaka K. In Situ Synthesis of Glycoconjugates on the Cell Surface: Selective Cell Imaging Using Low-Affinity Glycan Ligands. Middle Molecular Strategy 2021. [DOI: 10.1007/978-981-16-2458-2_4] [Reference Citation Analysis]
10 Novak D, Tomašič T, Krošelj M, Javornik U, Plavec J, Anderluh M, Kolenc Peitl P. Radiolabelled CCK2 R Antagonists Containing PEG Linkers: Design, Synthesis and Evaluation. ChemMedChem 2021;16:155-63. [PMID: 32643833 DOI: 10.1002/cmdc.202000392] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
11 Poret B, Desrues L, Bonin MA, Pédard M, Dubois M, Leduc R, Modzelewski R, Decazes P, Morin F, Vera P, Castel H, Bohn P, Gandolfo P. Development of Novel 111-In-Labelled DOTA Urotensin II Analogues for Targeting the UT Receptor Overexpressed in Solid Tumours. Biomolecules 2020;10:E471. [PMID: 32204509 DOI: 10.3390/biom10030471] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
12 Shahsavari S, Shaghaghi Z, Abedi SM, Hosseinimehr SJ. Evaluation of 99m Tc-HYNIC-(ser) 3 -LTVPWY peptide for glioblastoma imaging. International Journal of Radiation Biology 2020;96:502-9. [DOI: 10.1080/09553002.2020.1704906] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
13 Liu N, Shi Y, Guo J, Li H, Wang Q, Song M, Shi Z, He L, Su X, Xie J, Sun X. Radioiodinated tyrosine based carbon dots with efficient renal clearance for single photon emission computed tomography of tumor. Nano Res 2019;12:3037-43. [DOI: 10.1007/s12274-019-2549-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
14 Erdmann S, Niederstadt L, Koziolek EJ, Gómez JDC, Prasad S, Wagener A, von Hacht JL, Reinicke S, Exner S, Bandholtz S, Beindorff N, Brenner W, Grötzinger C. CMKLR1-targeting peptide tracers for PET/MR imaging of breast cancer. Theranostics 2019;9:6719-33. [PMID: 31588246 DOI: 10.7150/thno.34857] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
15 Erdmann S, Niederstadt L, Koziolek EJ, Castillo Gómez JD, Prasad S, Wagener A, von Hacht JL, Hallmann S, Exner S, Bandholtz S, Beindorff N, Brenner W, Grötzinger C. CMKLR1-targeting peptide tracers for PET/MR imaging of breast cancer.. [DOI: 10.1101/575902] [Reference Citation Analysis]
16 Allott L, Miranda C, Hayes A, Raynaud F, Cawthorne C, Smith G. Synthesis of a benzoxazinthione derivative of tanaproget and pharmacological evaluation for PET imaging of PR expression. EJNMMI Radiopharm Chem 2019;4:1. [PMID: 31659497 DOI: 10.1186/s41181-018-0054-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
17 Mankoff D. Why Nuclear Imaging and Radiotherapy? Radiopharmaceutical Chemistry 2019. [DOI: 10.1007/978-3-319-98947-1_1] [Reference Citation Analysis]
18 Chen CJ, Chan CH, Lin KL, Chen JH, Tseng CH, Wang PY, Chien CY, Yu HM, Lin WJ. 68Ga-labelled NOTA-RGD-GE11 peptide for dual integrin and EGFR-targeted tumour imaging. Nucl Med Biol 2019;68-69:22-30. [PMID: 30578136 DOI: 10.1016/j.nucmedbio.2018.11.003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
19 Mankoff DA, Katz SI. PET imaging for assessing tumor response to therapy. J Surg Oncol 2018;118:362-73. [PMID: 29938396 DOI: 10.1002/jso.25114] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
20 Ilhan-Ayisigi E, Yesil-Celiktas O. Silica-based organic-inorganic hybrid nanoparticles and nanoconjugates for improved anticancer drug delivery. Eng Life Sci 2018;18:882-92. [PMID: 32624882 DOI: 10.1002/elsc.201800038] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
21 Pereira PM, Abma L, Henry KE, Lewis JS. Imaging of human epidermal growth factor receptors for patient selection and response monitoring – From PET imaging and beyond. Cancer Letters 2018;419:139-51. [DOI: 10.1016/j.canlet.2018.01.052] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 4.8] [Reference Citation Analysis]
22 Okarvi SM, Maecke HR. Radiolabelled peptides in medical imaging. Peptide Applications in Biomedicine, Biotechnology and Bioengineering. Elsevier; 2018. pp. 431-83. [DOI: 10.1016/b978-0-08-100736-5.00019-3] [Cited by in Crossref: 6] [Article Influence: 1.2] [Reference Citation Analysis]
23 Qu X, Qiu P, Zhu Y, Yang M, Mao C. Guiding nanomaterials to tumors for breast cancer precision medicine: from tumor-targeting small-molecule discovery to targeted nanodrug delivery. NPG Asia Mater 2017;9:e452. [PMID: 29657602 DOI: 10.1038/am.2017.196] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 4.7] [Reference Citation Analysis]
24 Taichi M, Nomura S, Nakase I, Imamaki R, Kizuka Y, Ota F, Dohmae N, Kitazume S, Taniguchi N, Tanaka K. In Situ Ligation of High- and Low-Affinity Ligands to Cell Surface Receptors Enables Highly Selective Recognition. Adv Sci (Weinh) 2017;4:1700147. [PMID: 29201607 DOI: 10.1002/advs.201700147] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
25 Mercier MC, Dontenwill M, Choulier L. Selection of Nucleic Acid Aptamers Targeting Tumor Cell-Surface Protein Biomarkers. Cancers (Basel) 2017;9:E69. [PMID: 28635657 DOI: 10.3390/cancers9060069] [Cited by in Crossref: 56] [Cited by in F6Publishing: 58] [Article Influence: 9.3] [Reference Citation Analysis]
26 Hao D, Sun L, Hu X, Hao X. 99mTc-LHRH in tumor receptor imaging. Oncol Lett 2017;14:569-78. [PMID: 28693207 DOI: 10.3892/ol.2017.6246] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
27 Summer D, Grossrubatscher L, Petrik M, Michalcikova T, Novy Z, Rangger C, Klingler M, Haas H, Kaeopookum P, von Guggenberg E, Haubner R, Decristoforo C. Developing Targeted Hybrid Imaging Probes by Chelator Scaffolding. Bioconjug Chem 2017;28:1722-33. [PMID: 28462989 DOI: 10.1021/acs.bioconjchem.7b00182] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
28 Liu H, Chen Y, Wu S, Song F, Zhang H, Tian M. Molecular imaging using PET and SPECT for identification of breast cancer subtypes. Nucl Med Commun 2016;37:1116-24. [PMID: 27438531 DOI: 10.1097/MNM.0000000000000576] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
29 Tekdasc DA, Atilla D, Ahsen V, Gurek AG. 11 Tetrapyrrole-based theranostic combinations of photodynamic action and magnetic resonance imaging. Imaging in Photodynamic Therapy 2017. [DOI: 10.1201/9781315278179-12] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
30 Sunderland KS, Yang M, Mao C. Phage-Enabled Nanomedicine: From Probes to Therapeutics in Precision Medicine. Angew Chem Int Ed Engl 2017;56:1964-92. [PMID: 27491926 DOI: 10.1002/anie.201606181] [Cited by in Crossref: 101] [Cited by in F6Publishing: 108] [Article Influence: 16.8] [Reference Citation Analysis]
31 Sunderland KS, Yang M, Mao C. Nanomedizin auf Phagenbasis: von Sonden zu Therapeutika für eine Präzisionsmedizin. Angew Chem 2017;129:1992-2022. [DOI: 10.1002/ange.201606181] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
32 Chudgar AV, Mankoff DA. Molecular Imaging and Precision Medicine in Breast Cancer. PET Clin 2017;12:39-51. [PMID: 27863565 DOI: 10.1016/j.cpet.2016.08.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
33 Mankoff DA, Edmonds CE, Farwell MD, Pryma DA. Development of Companion Diagnostics. Semin Nucl Med 2016;46:47-56. [PMID: 26687857 DOI: 10.1053/j.semnuclmed.2015.09.002] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 4.4] [Reference Citation Analysis]
34 Valliant JF. A Bridge Not Too Far: Linking Disciplines Through Molecular Imaging Probes. J Nucl Med Technol 2016;44:173-83. [DOI: 10.2967/jnumed.109.068312] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
35 Shi J, Wang F, Liu S. Radiolabeled cyclic RGD peptides as radiotracers for tumor imaging. Biophys Rep 2016;2:1-20. [PMID: 27819026 DOI: 10.1007/s41048-016-0021-8] [Cited by in Crossref: 51] [Cited by in F6Publishing: 53] [Article Influence: 7.3] [Reference Citation Analysis]
36 Pang B, Zhao Y, Luehmann H, Yang X, Detering L, You M, Zhang C, Zhang L, Li ZY, Ren Q, Liu Y, Xia Y. ⁶⁴Cu-Doped PdCu@Au Tripods: A Multifunctional Nanomaterial for Positron Emission Tomography and Image-Guided Photothermal Cancer Treatment. ACS Nano 2016;10:3121-31. [PMID: 26824412 DOI: 10.1021/acsnano.5b07968] [Cited by in Crossref: 84] [Cited by in F6Publishing: 87] [Article Influence: 12.0] [Reference Citation Analysis]
37 Weissleder R, Nahrendorf M. Advancing biomedical imaging. Proc Natl Acad Sci U S A 2015;112:14424-8. [PMID: 26598657 DOI: 10.1073/pnas.1508524112] [Cited by in Crossref: 88] [Cited by in F6Publishing: 96] [Article Influence: 12.6] [Reference Citation Analysis]
38 Okarvi SM, Maecke HR. Radiometallo-Labeled Peptides in Tumor Diagnosis and Targeted Radionuclide Therapy. Insights from Imaging in Bioinorganic Chemistry. Elsevier; 2016. pp. 341-96. [DOI: 10.1016/bs.adioch.2015.11.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
39 Urbain JC. Coagulation Factor and Theranostics: A New Paradigm in Molecular Imaging. J Nucl Med 2016;57:7-8. [DOI: 10.2967/jnumed.115.165852] [Reference Citation Analysis]
40 Edmonds CE, Mankoff DA. Novel Imaging Based Biomarkers in Breast Cancer. Molecular Pathology of Breast Cancer 2016. [DOI: 10.1007/978-3-319-41761-5_13] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
41 Bardajee GR, Mohammadi M, Kakavand N. Copper(II)-diaminosarcophagine-functionalized SBA-15: a heterogeneous nanocatalyst for the synthesis of benzimidazole, benzoxazole and benzothiazole derivatives under solvent-free conditions: The application of Cu(II)-DiAmSar/SBA-15 in organic synthesis. Appl Organometal Chem 2016;30:51-8. [DOI: 10.1002/aoc.3400] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
42 Allott L, Smith G, Aboagye EO, Carroll L. PET Imaging of Steroid Hormone Receptor Expression. Mol Imaging 2015;14:7290.2015.00026. [DOI: 10.2310/7290.2015.00026] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
43 Liu S. Radiolabeled Cyclic RGD Peptide Bioconjugates as Radiotracers Targeting Multiple Integrins. Bioconjug Chem 2015;26:1413-38. [PMID: 26193072 DOI: 10.1021/acs.bioconjchem.5b00327] [Cited by in Crossref: 72] [Cited by in F6Publishing: 74] [Article Influence: 9.0] [Reference Citation Analysis]
44 Mahajan A, Goh V, Basu S, Vaish R, Weeks AJ, Thakur MH, Cook GJ. Bench to bedside molecular functional imaging in translational cancer medicine: to image or to imagine? Clin Radiol. 2015;70:1060-1082. [PMID: 26187890 DOI: 10.1016/j.crad.2015.06.082] [Cited by in Crossref: 39] [Cited by in F6Publishing: 44] [Article Influence: 4.9] [Reference Citation Analysis]
45 Sharma P, Kumar R, Alavi A. PET/Computed Tomography Using New Radiopharmaceuticals in Targeted Therapy. PET Clin 2015;10:495-505. [PMID: 26384596 DOI: 10.1016/j.cpet.2015.05.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
46 Yu H, Chen J, Lin K, Lin W. Synthesis of 68 Ga-labeled NOTA-RGD-GE11 heterodimeric peptide for dual integrin and epidermal growth factor receptor-targeted tumor imaging: A new 68Ga labeled NOTA-RGD-GE11 heterodimeric peptide. J Label Compd Radiopharm 2015;58:299-303. [DOI: 10.1002/jlcr.3296] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
47 European Society of Radiology (ESR). Medical imaging in personalised medicine: a white paper of the research committee of the European Society of Radiology (ESR). Insights Imaging 2015;6:141-55. [PMID: 25763994 DOI: 10.1007/s13244-015-0394-0] [Cited by in Crossref: 78] [Cited by in F6Publishing: 84] [Article Influence: 9.8] [Reference Citation Analysis]
48 Greene LR, Wilkinson D. The role of general nuclear medicine in breast cancer. J Med Radiat Sci 2015;62:54-65. [PMID: 26229668 DOI: 10.1002/jmrs.97] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
49 Jung KH, Lee KH. Molecular imaging in the era of personalized medicine. J Pathol Transl Med. 2015;49:5-12. [PMID: 25812652 DOI: 10.4132/jptm.2014.10.24] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 3.1] [Reference Citation Analysis]
50 Liang S, Ma Y, Guo J, Guo R, Wang H. 18F-radiolabeled analogs of peptide RGD-A7R for simultaneous PET imaging of both αvβ3 and VEGF in tumors. J Radioanal Nucl Chem 2014. [DOI: 10.1007/s10967-014-3689-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
51 Bertolini R, Goepfert C, Andrieu T, Nichols S, Walter MA, Frey FJ, McCammon JA, Frey BM. 18F-RB390: innovative ligand for imaging the T877A androgen receptor mutant in prostate cancer via positron emission tomography (PET). Prostate 2015;75:348-59. [PMID: 25358634 DOI: 10.1002/pros.22919] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
52 Samkoe KS, Tichauer KM, Gunn JR, Wells WA, Hasan T, Pogue BW. Quantitative in vivo immunohistochemistry of epidermal growth factor receptor using a receptor concentration imaging approach. Cancer Res 2014;74:7465-74. [PMID: 25344226 DOI: 10.1158/0008-5472.CAN-14-0141] [Cited by in Crossref: 45] [Cited by in F6Publishing: 49] [Article Influence: 5.0] [Reference Citation Analysis]
53 Mammatas LH, Verheul HM, Hendrikse NH, Yaqub M, Lammertsma AA, Menke-van der Houven van Oordt CW. Molecular imaging of targeted therapies with positron emission tomography: the visualization of personalized cancer care. Cell Oncol (Dordr) 2015;38:49-64. [PMID: 25248503 DOI: 10.1007/s13402-014-0194-4] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.2] [Reference Citation Analysis]
54 Mankoff DA, Pryma DA. The contribution of physics to Nuclear Medicine: physicians' perspective on future directions. EJNMMI Phys 2014;1:5. [PMID: 26501447 DOI: 10.1186/2197-7364-1-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
55 Sugiura G, Kühn H, Sauter M, Haberkorn U, Mier W. Radiolabeling strategies for tumor-targeting proteinaceous drugs. Molecules 2014;19:2135-65. [PMID: 24552984 DOI: 10.3390/molecules19022135] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 3.9] [Reference Citation Analysis]
56 Padhani AR, Makris A, Gall P, Collins DJ, Tunariu N, de Bono JS. Therapy monitoring of skeletal metastases with whole-body diffusion MRI: WB-DWI for Bone Metastases Monitoring. J Magn Reson Imaging 2014;39:1049-78. [DOI: 10.1002/jmri.24548] [Cited by in Crossref: 83] [Cited by in F6Publishing: 87] [Article Influence: 9.2] [Reference Citation Analysis]
57 El-salam M, Reda S, Lotfi S, Refaat T, El-abd E. Imaging Techniques in Cancer Diagnosis. Cancer Biomarkers 2014. [DOI: 10.1201/b16389-4] [Reference Citation Analysis]
58 Liu Y. Advances in Radiotracer Development for Molecular Imaging. Molecular Imaging of Small Animals 2014. [DOI: 10.1007/978-1-4939-0894-3_9] [Reference Citation Analysis]
59 García-figueiras R, Padhani AR. New Therapies and Functional-Molecular Imaging. Functional Imaging in Oncology 2014. [DOI: 10.1007/978-3-642-40412-2_5] [Reference Citation Analysis]
60 Pysz MA, Willmann JK. Applications of Molecular Small-Animal Imaging in Oncology. Molecular Imaging of Small Animals 2014. [DOI: 10.1007/978-1-4939-0894-3_21] [Reference Citation Analysis]
61 Molecular Imaging. Nuclear Medicine 2014. [DOI: 10.1016/b978-0-323-08299-0.00002-x] [Reference Citation Analysis]
62 Moyer BR. Imaging Platforms and Drug Development: An Introduction. Pharmaco-Imaging in Drug and Biologics Development 2014. [DOI: 10.1007/978-1-4614-8247-5_1] [Reference Citation Analysis]
63 Feng B, Guo L, Wang L, Li F, Lu J, Gao J, Fan C, Huang Q. A Graphene Oxide-Based Fluorescent Biosensor for the Analysis of Peptide–Receptor Interactions and Imaging in Somatostatin Receptor Subtype 2 Overexpressed Tumor Cells. Anal Chem 2013;85:7732-7. [DOI: 10.1021/ac4009463] [Cited by in Crossref: 62] [Cited by in F6Publishing: 64] [Article Influence: 6.2] [Reference Citation Analysis]
64 George GP, Pisaneschi F, Stevens E, Nguyen QD, Åberg O, Spivey AC, Aboagye EO. Scavenging strategy for specific activity improvement: application to a new CXCR4-specific cyclopentapeptide positron emission tomography tracer. J Labelled Comp Radiopharm 2013;56:679-85. [PMID: 25196030 DOI: 10.1002/jlcr.3095] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
65 Macis G, Di Giovanni S, Di Franco D, Bonomo L. Future Perspectives for Diagnostic Imaging in Urology: From Anatomic and Functional to Molecular Imaging. Urologia 2013;80:29-41. [DOI: 10.5301/ru.2013.10792] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
66 Cervino AR, Burei M, Mansi L, Evangelista L. Molecular pathways and molecular imaging in breast cancer: an update. Nucl Med Biol 2013;40:581-91. [PMID: 23602603 DOI: 10.1016/j.nucmedbio.2013.03.002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
67 Zeng D, Anderson CJ. Rapid and sensitive LC-MS approach to quantify non-radioactive transition metal impurities in metal radionuclides. Chem Commun 2013;49:2697. [DOI: 10.1039/c3cc39071c] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
68 Okarvi SM, Maecke HR. Peptides for Nuclear Medicine Therapy: Chemical Properties and Production. Therapeutic Nuclear Medicine 2013. [DOI: 10.1007/174_2013_921] [Reference Citation Analysis]
69 Ambrosetti MC, Volterrani D, Guidoccio F, Bodei L, Orsini F, Mariani G, Ferdeghini M. Functional Imaging and Peptide Receptor Radionuclide Therapy. Uncommon Pancreatic Neoplasms 2013. [DOI: 10.1007/978-88-470-2673-5_11] [Reference Citation Analysis]
70 Fanti S, Maffione AM. Pancreatic Cancer. Nuclear Oncology 2013. [DOI: 10.1007/978-0-387-48894-3_17] [Reference Citation Analysis]
71 Lee JH, Eubank WB, Mankoff DA. Breast Cancer. Nuclear Oncology 2013. [DOI: 10.1007/978-0-387-48894-3_12] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
72 Bodei L, Boni G, Paganelli G, Volterrani D. Neuroendocrine Tumors. Nuclear Oncology 2013. [DOI: 10.1007/978-0-387-48894-3_18] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
73 Evans MJ. Measuring oncogenic signaling pathways in cancer with PET: an emerging paradigm from studies in castration-resistant prostate cancer. Cancer Discov 2012;2:985-94. [PMID: 23043150 DOI: 10.1158/2159-8290.CD-12-0178] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
74 Zhang X, Bloch S, Akers W, Achilefu S. Near-infrared molecular probes for in vivo imaging. Curr Protoc Cytom. 2012;Chapter 12:Unit12.27. [PMID: 22470154 DOI: 10.1002/0471142956.cy1227s60] [Cited by in Crossref: 43] [Cited by in F6Publishing: 54] [Article Influence: 3.9] [Reference Citation Analysis]
75 Nguyen V, Conyers JM, Zhu D, Gibo DM, Hantgan RR, Larson SM, Debinski W, Mintz A. A novel ligand delivery system to non-invasively visualize and therapeutically exploit the IL13Rα2 tumor-restricted biomarker. Neuro Oncol 2012;14:1239-53. [PMID: 22952195 DOI: 10.1093/neuonc/nos211] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
76 Koopmans KP, Glaudemans AW. Rationale for the use of radiolabelled peptides in diagnosis and therapy. Eur J Nucl Med Mol Imaging. 2012;39 Suppl 1:S4-10. [PMID: 22388630 DOI: 10.1007/s00259-011-2038-z] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 2.3] [Reference Citation Analysis]
77 Núñez Miller R, Pozo MA. Non-FDG PET in oncology. Clin Transl Oncol 2011;13:780-6. [PMID: 22082641 DOI: 10.1007/s12094-011-0733-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
78 Kuil J, Buckle T, van Leeuwen FW. Imaging agents for the chemokine receptor 4 (CXCR4). Chem Soc Rev 2012;41:5239-61. [PMID: 22743644 DOI: 10.1039/c2cs35085h] [Cited by in Crossref: 65] [Cited by in F6Publishing: 69] [Article Influence: 5.9] [Reference Citation Analysis]
79 Fani M, Maecke HR, Okarvi SM. Radiolabeled peptides: valuable tools for the detection and treatment of cancer. Theranostics 2012;2:481-501. [PMID: 22737187 DOI: 10.7150/thno.4024] [Cited by in Crossref: 211] [Cited by in F6Publishing: 219] [Article Influence: 19.2] [Reference Citation Analysis]
80 Jones T, Price P. Development and experimental medicine applications of PET in oncology: a historical perspective. Lancet Oncol 2012;13:e116-25. [PMID: 22381934 DOI: 10.1016/S1470-2045(11)70183-8] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 2.6] [Reference Citation Analysis]
81 Specht JM, Mankoff DA. Advances in molecular imaging for breast cancer detection and characterization. Breast Cancer Res 2012;14:206. [PMID: 22423895 DOI: 10.1186/bcr3094] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 2.4] [Reference Citation Analysis]
82 Kircher MF, Hricak H, Larson SM. Molecular imaging for personalized cancer care. Mol Oncol 2012;6:182-95. [PMID: 22469618 DOI: 10.1016/j.molonc.2012.02.005] [Cited by in Crossref: 122] [Cited by in F6Publishing: 129] [Article Influence: 11.1] [Reference Citation Analysis]
83 Tsujikawa T, Yoshida Y, Maeda H, Tsuchida T, Mori T, Kiyono Y, Kimura H, Okazawa H. Oestrogen-related tumour phenotype: positron emission tomography characterisation with ¹⁸F-FDG and ¹⁸F-FES. Br J Radiol 2012;85:1020-4. [PMID: 22337690 DOI: 10.1259/bjr/26645378] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
84 Sun L, Luo J, Mackey LV, Morris LM, Franko-Tobin LG, LePage KT, Coy DH. Investigation of cancer cell lines for peptide receptor-targeted drug development. J Drug Target 2011;19:719-30. [PMID: 21830941 DOI: 10.3109/1061186X.2011.558089] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
85 Sukerkar PA, MacRenaris KW, Townsend TR, Ahmed RA, Burdette JE, Meade TJ. Synthesis and biological evaluation of water-soluble progesterone-conjugated probes for magnetic resonance imaging of hormone related cancers. Bioconjug Chem 2011;22:2304-16. [PMID: 21972997 DOI: 10.1021/bc2003555] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 2.6] [Reference Citation Analysis]
86 Lee DY, Li KC. Molecular theranostics: a primer for the imaging professional. AJR Am J Roentgenol 2011;197:318-24. [PMID: 21785076 DOI: 10.2214/AJR.11.6797] [Cited by in Crossref: 59] [Cited by in F6Publishing: 64] [Article Influence: 4.9] [Reference Citation Analysis]
87 Sukerkar PA, MacRenaris KW, Meade TJ, Burdette JE. A steroid-conjugated magnetic resonance probe enhances contrast in progesterone receptor expressing organs and tumors in vivo. Mol Pharm 2011;8:1390-400. [PMID: 21736390 DOI: 10.1021/mp200219e] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 1.9] [Reference Citation Analysis]
88 Kim E, Jeong M, Kim DW, Jeong H, Lim ST, Sohn M. Iodine 125-labeled mesenchymal-epithelial transition factor binding peptide-click-cRGDyk heterodimer for glioma imaging. Cancer Science 2011;102:1516-21. [DOI: 10.1111/j.1349-7006.2011.01983.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
89 Pham D, Zhang L, Chen B, Fung Jones E. Biopolymer, Dendrimer, and Liposome Nanoplatforms for Optical Molecular Imaging. Nanoplatform-Based Molecular Imaging 2011. [DOI: 10.1002/9780470767047.ch8] [Reference Citation Analysis]
90 Rauwerdink AM, Weaver JB. Concurrent quantification of multiple nanoparticle bound states. Med Phys 2011;38:1136-40. [PMID: 21520825 DOI: 10.1118/1.3549762] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 2.3] [Reference Citation Analysis]
91 Peterson LM, Kurland BF, Link JM, Schubert EK, Stekhova S, Linden HM, Mankoff DA. Factors influencing the uptake of 18F-fluoroestradiol in patients with estrogen receptor positive breast cancer. Nucl Med Biol 2011;38:969-78. [PMID: 21982568 DOI: 10.1016/j.nucmedbio.2011.03.002] [Cited by in Crossref: 53] [Cited by in F6Publishing: 45] [Article Influence: 4.4] [Reference Citation Analysis]
92 Huang WY, Davis JJ. Multimodality and nanoparticles in medical imaging. Dalton Trans 2011;40:6087-103. [PMID: 21409202 DOI: 10.1039/c0dt01656j] [Cited by in Crossref: 75] [Cited by in F6Publishing: 76] [Article Influence: 6.3] [Reference Citation Analysis]
93 . BIOMARKERS AND PUBLIC–PRIVATE PARTNERSHIPS. Translational Medicine and Drug Discovery 2011. [DOI: 10.1017/cbo9780511976087.010] [Reference Citation Analysis]
94 T. Tauscher J, Schwarz AJ. IMAGING BIOMARKERS IN DRUG DEVELOPMENT: CASE STUDIES. Translational Medicine and Drug Discovery 2011. [DOI: 10.1017/cbo9780511976087.012] [Reference Citation Analysis]
95 Tan EH, Tan CH. Imaging of gastroenteropancreatic neuroendocrine tumors. World J Clin Oncol 2011; 2(1): 28-43 [PMID: 21603312 DOI: 10.5306/wjco.v2.i1.28] [Cited by in CrossRef: 60] [Cited by in F6Publishing: 68] [Article Influence: 5.0] [Reference Citation Analysis]
96 Mankoff DA. Imaging Studies in Anticancer Drug Development. Principles of Anticancer Drug Development 2011. [DOI: 10.1007/978-1-4419-7358-0_11] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
97 Wang L, Li C. pH responsive fluorescence nanoprobe imaging of tumors by sensing the acidic microenvironment. J Mater Chem 2011;21:15862. [DOI: 10.1039/c1jm12072g] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 3.8] [Reference Citation Analysis]
98 Pysz MA, Gambhir SS, Willmann JK. Molecular imaging: current status and emerging strategies. Clin Radiol. 2010;65:500-516. [PMID: 20541650 DOI: 10.1016/j.crad.2010.03.011] [Cited by in Crossref: 376] [Cited by in F6Publishing: 401] [Article Influence: 28.9] [Reference Citation Analysis]
99 Li Z, Conti PS. Radiopharmaceutical chemistry for positron emission tomography. Adv Drug Deliv Rev 2010;62:1031-51. [PMID: 20854860 DOI: 10.1016/j.addr.2010.09.007] [Cited by in Crossref: 142] [Cited by in F6Publishing: 149] [Article Influence: 10.9] [Reference Citation Analysis]
100 Lee S, Xie J, Chen X. Peptides and peptide hormones for molecular imaging and disease diagnosis. Chem Rev 2010;110:3087-111. [PMID: 20225899 DOI: 10.1021/cr900361p] [Cited by in Crossref: 239] [Cited by in F6Publishing: 251] [Article Influence: 18.4] [Reference Citation Analysis]
101 Tafreshi NK, Kumar V, Morse DL, Gatenby RA. Molecular and Functional Imaging of Breast Cancer. Cancer Control 2010;17:143-55. [DOI: 10.1177/107327481001700302] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 2.2] [Reference Citation Analysis]
102 Olafsen T, Wu AM. Antibody vectors for imaging. Semin Nucl Med. 2010;40:167-181. [PMID: 20350626 DOI: 10.1053/j.semnuclmed.2009.12.005] [Cited by in Crossref: 155] [Cited by in F6Publishing: 162] [Article Influence: 11.9] [Reference Citation Analysis]
103 Moody JB, Murphy PS, Ficaro EP. Imaging as a Localized Biomarker: Opportunities and Challenges. Pharmaceutical Sciences Encyclopedia 2010. [DOI: 10.1002/9780470571224.pse255] [Reference Citation Analysis]
104 Tan EH, Goh SW. Exploring new frontiers in molecular imaging: Emergence of 68Ga PET/CT. World J Radiol 2010; 2(2): 55-67 [PMID: 21160919 DOI: 10.4329/wjr.v2.i2.55] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
105 Rauwerdink AM, Weaver JB. Measurement of molecular binding using the Brownian motion of magnetic nanoparticle probes. Appl Phys Lett 2010;96:033702. [DOI: 10.1063/1.3291063] [Cited by in Crossref: 66] [Cited by in F6Publishing: 67] [Article Influence: 5.1] [Reference Citation Analysis]
106 Zinn KR. Overview of Cancer Detection and Monitoring Strategies. Optical Imaging of Cancer 2010. [DOI: 10.1007/978-0-387-93874-5_5] [Reference Citation Analysis]
107 Wyatt SK, Manning HC, Bai M, Bailey SN, Gallant P, Ma G, McIntosh L, Bornhop DJ. Molecular imaging of the translocator protein (TSPO) in a pre-clinical model of breast cancer. Mol Imaging Biol 2010;12:349-58. [PMID: 19949989 DOI: 10.1007/s11307-009-0270-8] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 1.6] [Reference Citation Analysis]
108 Worsley DF, Wilson DC, Powe JE, Benard F. Impact of F-18 fluorodeoxyglucose positron emission tomography-computed tomography on oncologic patient management: first 2 years' experience at a single Canadian cancer center. Can Assoc Radiol J 2010;61:13-8. [PMID: 19819103 DOI: 10.1016/j.carj.2009.07.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
109 Mankoff DA, Lee JH, Eubank WB. Breast Cancer Imaging with Novel PET Tracers. PET Clinics 2009;4:371-80. [DOI: 10.1016/j.cpet.2009.10.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
110 Mankoff DA, Dehdashti F. Imaging tumor phenotype: 1 plus 1 is more than 2. J Nucl Med 2009;50:1567-9. [PMID: 19759107 DOI: 10.2967/jnumed.108.061044] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
111 Mishani E, Hagooly A. Strategies for molecular imaging of epidermal growth factor receptor tyrosine kinase in cancer. J Nucl Med 2009;50:1199-202. [PMID: 19617320 DOI: 10.2967/jnumed.109.062117] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 2.6] [Reference Citation Analysis]
112 Moyer BR, Barrett JA. Biomarkers and imaging: physics and chemistry for noninvasive analyses. Bioanalysis 2009;1:321-56. [DOI: 10.4155/bio.09.30] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
113 Wong FC, Kim EE. A review of molecular imaging studies reaching the clinical stage. European Journal of Radiology 2009;70:205-11. [DOI: 10.1016/j.ejrad.2009.01.049] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 1.7] [Reference Citation Analysis]
114 Lee JH, Rosen EL, Mankoff DA. The Role of Radiotracer Imaging in the Diagnosis and Management of Patients with Breast Cancer: Part 2—Response to Therapy, Other Indications, and Future Directions. J Nucl Med 2009;50:738-48. [DOI: 10.2967/jnumed.108.061416] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 1.6] [Reference Citation Analysis]
115 Mukherjee A, Wickstrom E, Thakur ML. Imaging oncogene expression. Eur J Radiol 2009;70:265-73. [PMID: 19264436 DOI: 10.1016/j.ejrad.2009.01.043] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
116 Liu Z, Yan Y, Chin FT, Wang F, Chen X. Dual integrin and gastrin-releasing peptide receptor targeted tumor imaging using 18F-labeled PEGylated RGD-bombesin heterodimer 18F-FB-PEG3-Glu-RGD-BBN. J Med Chem 2009;52:425-32. [PMID: 19113865 DOI: 10.1021/jm801285t] [Cited by in Crossref: 87] [Cited by in F6Publishing: 90] [Article Influence: 6.2] [Reference Citation Analysis]
117 Jabbari E. Targeted delivery with peptidomimetic conjugated self-assembled nanoparticles. Pharm Res 2009;26:612-30. [PMID: 19085091 DOI: 10.1007/s11095-008-9802-1] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
118 Mankoff DA. Molecular imaging as a tool for translating breast cancer science. Breast Cancer Res 2008;10 Suppl 1:S3. [PMID: 19091007 DOI: 10.1186/bcr2126] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
119 Gambhir SS. Molecualr imaging of cancer: from molecules to humans. Introduction. J Nucl Med 2008;49 Suppl 2:1S-4S. [PMID: 18523062 DOI: 10.2967/jnumed.108.053751] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 1.6] [Reference Citation Analysis]